Shareholders Will Probably Hold Off On Increasing Sisram Medical Ltd's (HKG:1696) CEO Compensation For The Time Being
Shareholders Will Probably Hold Off On Increasing Sisram Medical Ltd's (HKG:1696) CEO Compensation For The Time Being
Key Insights
主要見解
- Sisram Medical will host its Annual General Meeting on 24th of June
- Salary of US$863.0k is part of CEO Lior Dayan's total remuneration
- Total compensation is 330% above industry average
- Over the past three years, Sisram Medical's EPS grew by 31% and over the past three years, the total loss to shareholders 76%
- Sisram Medical將於6月24日舉行其年度股東大會。
- 總薪酬中的863.0k美元是CEO Lior Dayan的薪酬總額的一部分。
- 總補償比行業平均水平高330%。
- 在過去的三年中,Sisram Medical的每股收益增長了31%,而股東的總虧損爲76%。
Shareholders of Sisram Medical Ltd (HKG:1696) will have been dismayed by the negative share price return over the last three years. Despite positive EPS growth in the past few years, the share price hasn't tracked the fundamental performance of the company. The AGM coming up on the 24th of June could be an opportunity for shareholders to bring these concerns to the board's attention. Voting on resolutions such as executive remuneration and other matters could also be a way to influence management. We think shareholders might be reluctant to increase compensation for the CEO at the moment, according to our analysis below.
在過去的三年裏,Sisram Medical Ltd (HKG:1696)的股東可能爲負股價回報感到失望。儘管過去幾年EPS增長呈正值,但股價並未跟蹤公司的基本業績表現。6月24日即將舉行的股東大會可能是股東提出這些關切的機會。投票決議,如執行薪酬和其他事項,也可能是影響管理層的一種方式。根據我們以下的分析,我們認爲股東此時可能不願意增加CEO的補償。
How Does Total Compensation For Lior Dayan Compare With Other Companies In The Industry?
Lior Dayan的總補償與其他行業公司相比如何?
According to our data, Sisram Medical Ltd has a market capitalization of HK$1.8b, and paid its CEO total annual compensation worth US$1.5m over the year to December 2023. We note that's a decrease of 43% compared to last year. We note that the salary of US$863.0k makes up a sizeable portion of the total compensation received by the CEO.
據我們的數據,Sisram Medical Ltd的市值爲18億港元,並在截至2023年12月的一年內支付其CEO總年薪150萬美元。我們注意到,這與去年相比下降了43%。我們注意到,863.0k美元的薪水佔CEO獲得的總補償的相當大部分。
On comparing similar companies from the Hong Kong Medical Equipment industry with market caps ranging from HK$781m to HK$3.1b, we found that the median CEO total compensation was US$355k. Hence, we can conclude that Lior Dayan is remunerated higher than the industry median. What's more, Lior Dayan holds HK$3.5m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
在與市值從7.81億港元到31億港元的香港醫療設備行業類似的公司進行比較時,我們發現CEO的中位數總薪酬爲35.5萬美元。因此,我們可以得出結論,Lior Dayan的報酬高於行業中位數。此外,Lior Dayan以自己的名字持有350萬港元的公司股票,表明他們有很多利益關係。
Component | 2023 | 2022 | Proportion (2023) |
Salary | US$863k | US$1.3m | 57% |
Other | US$663k | US$1.4m | 43% |
Total Compensation | US$1.5m | US$2.7m | 100% |
組成部分 | 2023 | 2022 | 比例(2023) |
薪資 | 863k美元 | 130萬美元 | 57% |
其他 | 663,000美元 | 140萬美元 | 43% |
總補償 | 150萬美元 | 270萬美元 | 100% |
On an industry level, around 64% of total compensation represents salary and 36% is other remuneration. It's interesting to note that Sisram Medical allocates a smaller portion of compensation to salary in comparison to the broader industry. If salary is the major component in total compensation, it suggests that the CEO receives a higher fixed proportion of the total compensation, regardless of performance.
在行業層面上,約64%的總補償代表薪酬,36%是其他補償。有趣的是,與更廣泛的行業相比,Sisram Medical在薪酬分配方面分配更少的比例給薪酬。如果薪酬是總補償的主要組成部分,這表明CEO獲得了更高的固定比例的總補償,而不考慮表現。
![ceo-compensation](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240618/0-227bf64d33a6fb7ab37db7598263b6b5-0-0ec283bc78d4a58e74376d54e323479d.png/big)
Sisram Medical Ltd's Growth
Sisram Medical Ltd的增長
Sisram Medical Ltd's earnings per share (EPS) grew 31% per year over the last three years. Its revenue is up 1.4% over the last year.
Sisram Medical Ltd的每股收益過去三年增長了31%。其營業收入在過去一年增長了1.4%。
This demonstrates that the company has been improving recently and is good news for the shareholders. It's also good to see modest revenue growth, suggesting the underlying business is healthy. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..
Data I/O Corporation是否是一項不錯的投資?
Has Sisram Medical Ltd Been A Good Investment?
Sisram Medical Ltd是否是一個好的投資?
With a total shareholder return of -76% over three years, Sisram Medical Ltd shareholders would by and large be disappointed. Therefore, it might be upsetting for shareholders if the CEO were paid generously.
在過去三年中,Sisram Medical Ltd的總股東回報率爲-76%,股東們大體上會感到失望。因此,如果CEO被慷慨地支付,股東可能會感到沮喪。
To Conclude...
總之...
The fact that shareholders are sitting on a loss on the value of their shares in the past few years is certainly disconcerting. The stock's movement is disjointed with the company's earnings growth, which ideally should move in the same direction. If there are some unknown variables that are influencing the stock's price, surely shareholders would have some concerns. The upcoming AGM will be a chance for shareholders to question the board on key matters, such as CEO remuneration or any other issues they might have and revisit their investment thesis with regards to the company.
股東在過去幾年中持股價值下跌的事實無疑是令人不安的。股票的走勢與公司的盈利增長不一致,理想情況下應該走向同一方向。如果有一些未知的變量影響着股價,股東肯定會有一些顧慮。即將到來的股東大會將是股東就關鍵問題,例如CEO薪酬或其他問題進行質詢,並重新審視他們對公司的投資論點的機會。
While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. We did our research and spotted 1 warning sign for Sisram Medical that investors should look into moving forward.
雖然關注CEO薪酬很重要,但投資者也應考慮業務的其他方面。我們進行了研究,發現了Sisram Medical的1個警告信號,投資者在前進時應該注意。
Important note: Sisram Medical is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
重要提示:Sisram Medical是一家令人興奮的股票,但我們理解投資者可能正在尋找沒有負擔的資產負債表和高ROE低債務的暢銷產品。您可以在具有高ROE和低債務的有趣項目列表中找到更好的東西。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com